These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 34285050)

  • 1. Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting System.
    Pistor M; Hoepner AGF; Lin Y; Jung S; Bassetti CL; Chan A; Salmen A; Hoepner R
    Ann Rheum Dis; 2021 Dec; 80(12):1633-1635. PubMed ID: 34285050
    [No Abstract]   [Full Text] [Related]  

  • 2. Exploring pharmacogenetic difference using adverse event database: an example of clopidogrel and cardiovascular events.
    Joung KI; Kim KH; Hsieh CY; Shin JY
    Pharmacogenomics; 2020 Nov; 21(16):1157-1168. PubMed ID: 33118441
    [No Abstract]   [Full Text] [Related]  

  • 3. The Impact of Litigation-Associated Reports on Signal Identification in the US FDA's Adverse Event Reporting System.
    Muñoz MA; Dal Pan GJ
    Drug Saf; 2019 Oct; 42(10):1199-1201. PubMed ID: 31098918
    [No Abstract]   [Full Text] [Related]  

  • 4. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excess Ticagrelor Mortality in the Food and Drug Administration Adverse Event Reporting System: Time to Recount PLATO Trial Deaths.
    Serebruany VL; Fortmann SD; Cherepanov V; Litvinov O; Kim MH; Marciniak TA
    Am J Med; 2017 Jun; 130(6):e245-e246. PubMed ID: 28161342
    [No Abstract]   [Full Text] [Related]  

  • 6. Report slams US FDA's drug safety reform efforts.
    Bristol N
    Lancet; 2007 Mar; 369(9567):1072. PubMed ID: 17405202
    [No Abstract]   [Full Text] [Related]  

  • 7. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suspected drug-induced hepatic reactions reported to the FDA's adverse reaction system: an overview.
    Jones JK
    Semin Liver Dis; 1981 May; 1(2):157-67. PubMed ID: 7051297
    [No Abstract]   [Full Text] [Related]  

  • 9. Systemic Adverse Events Associated with Compounded Topical Pain Products.
    Kim J; Konkel K; Jones SC; McCulley L
    Drug Saf; 2020 May; 43(5):497-501. PubMed ID: 32248428
    [No Abstract]   [Full Text] [Related]  

  • 10. Evidence of Clinically Meaningful Drug-Drug Interaction With Concomitant Use of Colchicine and Clarithromycin.
    Villa Zapata L; Hansten PD; Horn JR; Boyce RD; Gephart S; Subbian V; Romero A; Malone DC
    Drug Saf; 2020 Jul; 43(7):661-668. PubMed ID: 32274687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the Fast Track Safe? A Safety Evaluation of the COVID-19 Drugs with Real-World Data.
    Kim HJ; Yoon JH; Lee K
    Stud Health Technol Inform; 2024 Jan; 310():1484-1485. PubMed ID: 38269708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021.
    Hause AM; Baggs J; Gee J; Marquez P; Myers TR; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(39):1379-1384. PubMed ID: 34591835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deaths Reported to the Vaccine Adverse Event Reporting System, United States, 1997-2013.
    Moro PL; Arana J; Cano M; Lewis P; Shimabukuro TT
    Clin Infect Dis; 2015 Sep; 61(6):980-7. PubMed ID: 26021988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004.
    Zinderman CE; Landow L; Wise RP
    J Vasc Surg; 2006 May; 43(5):1004-9. PubMed ID: 16678697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA's sentinel network: a monumental task.
    Young D
    Am J Health Syst Pharm; 2007 Apr; 64(8):800-1. PubMed ID: 17420189
    [No Abstract]   [Full Text] [Related]  

  • 16. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Woo EJ; Moro PL; Cano M; Jankosky C
    Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Miscategorization of Deaths in the US Food and Drug Administration Adverse Events Database.
    Meier L; Wang EY; Tomes M; Redberg RF
    JAMA Intern Med; 2020 Jan; 180(1):147-148. PubMed ID: 31589249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adverse drug reactions in patients with COVID-19].
    Ferreira-da-Silva R
    Cad Saude Publica; 2021; 37(11):e00228121. PubMed ID: 34816954
    [No Abstract]   [Full Text] [Related]  

  • 19. Adverse drug events and the Freedom of Information Act: an apple in Eden.
    Stang PE; Fox JL
    Ann Pharmacother; 1992 Feb; 26(2):238-43. PubMed ID: 1554939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing Different Adverse Effects Among Multiple Drugs Using FAERS Data.
    Huang J; Zhang X; Du J; Duan R; Yang L; Moore JH; Chen Y; Tao C
    Stud Health Technol Inform; 2017; 245():1268. PubMed ID: 29295353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.